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Abstract
Protein Z-dependent protease inhibitor (ZPI) and antithrombin III (AT3) are members of the serpin
superfamily of protease inhibitors that inhibit factor Xa (FXa) and other proteases in the coagulation
pathway. While experimental structural information is available for the interaction of AT3 with FXa,
at present there is no structural data regarding the interaction of ZPI with FXa, and the precise role
of this interaction in the blood coagulation pathway is poorly understood. In an effort to gain a
structural understanding of this system, we have built a solvent equilibrated three-dimensional
structural model of the Michaelis complex of human ZPI/FXa using homology modeling, protein–
protein docking and molecular dynamics simulation methods. Preliminary analysis of interactions
at the complex interface from our simulations suggests that the interactions of the reactive center
loop (RCL) and the exosite surface of ZPI with FXa are similar to those observed from X-ray crystal
structure-based simulations of AT3/FXa. However, detailed comparison of our modeled structure of
ZPI/FXa with that of AT3/FXa points to differences in interaction specificity at the reactive center
and in the stability of the inhibitory complex, due to the presence of a tyrosine residue at the P1
position in ZPI, instead of the P1 arginine residue in AT3. The modeled structure also shows specific
structural differences between AT3 and ZPI in the heparin-binding and flexible N-terminal tail
regions. Our structural model of ZPI/FXa is also compatible with available experimental information
regarding the importance for the inhibitory action of certain basic residues in FXa.
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Serpins (serine protease inhibitors) are involved in the regulation of several blood coagulation
proteases and play a key role in the control of thrombosis and hemostasis [1,2]. Protein Z-
dependent protease inhibitor (ZPI) is a member of the serpin superfamily of protease inhibitors
that inhibits factor Xa (FXa), factor IXa (FIXa) and factor XIa (FXIa) by different molecular
mechanisms [3–7]. ZPI can produce rapid inhibition of FXa in the presence of the cofactor
protein Z (PZ), negatively charged phospholipids and Ca2+ ions [3]. However, PZ is not
absolutely required for inhibition, and ZPI by itself can inhibit FXa, although at a much slower
rate (1,000-fold decrease in inhibition) [4]. ZPI therefore acts as an anticoagulant serpin. Low
levels of either ZPI or PZ have been shown to be associated with ischemic stroke and central
retinal vein or artery occlusion [8–10]. At the same time, ZPI is not the predominant
physiological inhibitor of the coagulation pathway; the major function is thought to be
dampening of the coagulation response prior to the formation of prothrombinase complex
[5].
The protein structures of serpins are characterized by three β-sheets (A, B and C), 8–9 α-helices
(hA–hI) and a reactive center loop (RCL) forming an extended, exposed conformation above
the body of the serpin scaffold [2,11]. From a structural point of view, ZPI can reasonably be
considered to be similar to other serpins. Human ZPI is a single chain protein with 423 residues
that have 26–31% sequence identity with the other serpins, including antithrombin III (AT3),
α1-antitrypsin (A1AT) and heparin cofactor II (HCII) for which three-dimensional (3D)
structures exist [3]. Sequence alignment of ZPI with other serpins (Fig. 1) predicts that the P1
residue at the reactive center of ZPI is a tyrosine. A study that constructed an altered form of
ZPI with the P1 residue mutated to an alanine found that it lacked inhibitory activity against
FXa [3].
Despite the sequence similarity of ZPI with other serpins and its inhibitory activity against
FXa, the structure of human ZPI is currently unresolved, with many unanswered questions
about the role of ZPI in the coagulation pathway. What structural factors lead to the difference
in inhibitory activity between ZPI and AT3? Is ZPI capable of binding to heparin like AT3 and
HCII? How does PZ enhance the inhibitory activity of ZPI against FXa? We have recently
proposed a solvent-equilibrated atomic structural model of PZ with bound Ca2+ ions [12]. In
order to address the questions raised above, it would be desirable to build a realistic structural
model of ZPI bound to FXa, to gain understanding of the atomic details of the interaction.
What is the nature of the PZ, ZPI and FXa interaction? We know that PZ and ZPI form a
complex in plasma [13] with a Kd of ~ 7 nM [14], and we know the plasma concentration of
PZ and ZPI to be 40 nM [15] and 53 nM [4], respectively. Indirect, but not structurally
conclusive, evidence suggests a ternary complex on the membrane surface. If, however, we
compute the plasma concentration of ZPI (53 nM) as molecules/Å3 (3.2×10−11 molecules/
Å3) and compare this to the estimated surface concentration (0.5×10−7 molecules/Å3), we find
that the concentration of ZPI at the surface is enhanced by a factor of ~1,600 over that in plasma.
Here, we are estimating a PZ/ZPI complex to occupy 106 Å3 on the membrane surface, that
approximately 10% of the surface is occupied by the complex (through the Gla domain of PZ),
and that half of the PZ molecules at the surface will be bound to ZPI. These estimates are
conservative so as not to bias the conclusion. Thus, following this reasoning, we are led to the
simple result that a model of action of ZPI does not require a ternary complex of ZPI, PZ and
FXa. Instead, a reasonable model is that PZ transports ZPI to the membrane surface, enhances
ZPI concentration at the surface by more than 103-fold, where the ZPI can then bind membrane-
bound FXa for its inhibitory action. Thus, we focus on a binary model of ZPI/FXa as the central
inhibitory unit.
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Is there good structural data on which to base a model of ZPI/FXa? Fortunately, a recent 3D
X-ray crystal structure exists for a homologous system: the AT3 (S195A)/FXa/ pentasaccharide
complex [16]. Although structural data for AT3 and HCII with thrombin (S195A) are also
known, it is most reasonable to employ the AT3/FXa (S195A) as a primary modeling template
due to thrombin versus FXa structural and sequence differences. The pentasaccharide moiety
can be discarded since it is used as a heparin model in the X-ray work and the action of ZPI is
known to not be enhanced by heparin [4]. Since we intend to employ a longtime molecular
dynamics (MD) simulation on the initial modeled structure, significant conformational
adjustments can occur to remove template bias and therefore accommodate the required
structural changes in the ZPI model.
Using the sequence information for human ZPI, we have employed several computational
modeling approaches to build a structural model of human ZPI in complex with FXa. Molecular
dynamics simulations of both the X-ray crystal structure of the AT3/FXa complex [16] and
our modeled structure of ZPI/FXa in explicitly solvated systems, followed by molecular
mechanics Poisson-Boltzmann/surface area (MM-PBSA) calculations [17] were then used to
estimate structural features potentially responsible for the differences in inhibitory activities
between AT3 and ZPI. The derived structural model for ZPI/FXa provides new atomistic
understanding of the functional role of ZPI.
Methods
Construction of ZPI/FXa model
Two different approaches were adopted to build a structural model of the ZPI/FXa complex.
In the first approach, we built a model of the complex through homology modeling, starting
from a multiple sequence alignment of ZPI with AT3, A1AT and HCII, and using the X-ray
crystal structure of AT3/FXa (PDB code 2GD4) [16] as the single structural template. Multiple
models of the complex were built using MODELLER 9v1 [18] and the best model was selected
based on stereochemical and energetic evaluations. This model was then explicitly solvated
and subjected to 25 ns MD simulation to obtain the final model of the complex.
In the second approach, we built a model of the ZPI/FXa complex using a protein–protein
docking method, starting from a homology model of ZPI and an X-ray crystal structure of FXa.
The rationale was that, although the flexible RCL region of ZPI probably interacts with the
active site of FXa in a manner similar to AT3 and other serpins, the remainder of the interaction
surface between ZPI and FXa could be different compared to AT3, owing to different surface
complementarities and also to the slightly shorter length of the RCL, due to a three-amino-acid
deletion in the C-terminal side of the reactive bond of ZPI (Fig. 1). In order to account for this
possibility, protein–protein docking was used to explore ZPI binding to FXa.
Homology modeling
The amino acid sequence of human ZPI was retrieved from Swiss-Prot (UniProt entry
Q9UK55) [19]. For the first approach, as mentioned above, a homology model of the ZPI/FXa
complex was built using the X-ray crystal structure of AT3/FXa (PDB code 2GD4) as the single
structural template. However for building a reliable sequence alignment, a multiple sequence
alignment of ZPI with AT3, A1AT and HCII sequences was created with CLUSTALW [20],
using the BLOSUM matrices for scoring the alignments, and this alignment (Fig. 1) was then
used to build several structural models using MODELLER.
In order to build a structural model of ZPI alone for the protein–protein docking approach, a
model of ZPI was built based on its homology to other serpins with known 3D structure. A
multiple sequence alignment of ZPI with AT3, A1AT and HCII sequences was created with
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CLUSTALW (Fig. 1), and their corresponding X-ray structures (PDB entry 2ANT [21], 1QLP
[22] and 1JMJ [23], respectively) were used as structural templates for the homology modeling.
The main difference between the native and activated (bound) forms of serpins is in the
conformation of the RCL region. The native form is usually in a compact conformation in
which the N-terminal region of RCL is partially inserted into the top of β-sheet A, whereas the
activated form is in an extended conformation in which the hinge region of RCL has been
expelled from β-sheet A, with a release of constraints on the RCL [24]. Since our aim was to
build a complex structure of activated ZPI with FXa, the RCL region of ZPI in this approach
was modeled based on a proteinase-bound conformation. The structures of AT3 bound to
thrombin (1TB6) [25] and FXa (2GD4) [16] in the presence of heparin were used to model the
RCL region, while the remainder of the structure was modeled using all three serpins.
The obtained alignments from CLUSTALW were checked for insertions and deletions in the
structurally conserved regions, especially the RCL region between the P4–P4′ residues and
also fine-tuned manually. The best alignment (Fig. 1) was selected based on both the alignment
score as well as the reciprocal positions of the conserved residues in the RCL region. The
resulting alignments, for each case, were used as input to construct homology models of ZPI
and ZPI/FXa using MODELLER. Three-dimensional models were built based on a distance
restraint algorithm imposed from the multiple sequence alignment of the target sequence with
the template structures, applying the CHARMM force field [26]. An optimization method
involving conjugate gradients and MD with simulated annealing, available in MODELLER,
was employed to minimize violations of spatial restraints. For the model building process,
default parameters included in the “automodel” class were used. To guarantee sufficient
conformational sampling of each active site residue, an ensemble of 30 models was built, from
which the best final model was selected based on evaluation of stereochemical values from
PROCHECK [27], the objective function from MODELLER and by visual inspection. The
models were also assessed using the Verify3D algorithm [28,29] to identify any region of
improper folding.
Protein–protein docking
Since the serpin mechanism of protease inhibition involves the formation of an encounter
complex (Michaelis complex) where the RCL region is recognized by the protease as a substrate
[2], a truncated region of RCL, namely P3-P1′ residues (Thr385–Ser388), from the homology
model was kept in place in the catalytic site of FXa. The remainder of the ZPI structure, except
the RCL, was then docked to FXa using a modified version of the docking program FTDOCK
[30]. The docking approach was based on surface complementarity with knowledge-based
distance constraints applied to improve the conformational search efficiency. Explicit distance
constraints were imposed in ZPI between the P3 residue (Thr385) and the C-terminal residue
to sheet A (Val369) and between P1′ residue (Ser388) and Val392, based on the distances
between their Cα atoms obtained from our ZPI model. One final model was picked from the
docking solutions based on surface complementarity and residue pair potential scores. To pick
the final model, the docking solutions were clustered based on the central position of the mobile
molecule with respect to the static molecule, and the solution with the best score from the
largest cluster was picked. The remainder of the RCL loop was then built using loop modeling
techniques implemented in SYBYL 7.2 (Tripos) to obtain a model of the ZPI/FXa complex.
MD simulations and MM-PBSA calculations
A stepwise structure refinement for the two homology models (ZPI by itself, and ZPI in
complex with FXa) was performed through a MD simulation, to obtain solvent-equilibrated
models and to remove bad contacts. All MD simulations were performed using PMEMD9 in
the AMBER9 [31] suite of molecular modeling programs. Force field parameters used were
taken from the ff99SB forcefield included in the AMBER9 MD package. Four different systems
Chandrasekaran et al. Page 4













were set up for final MD simulations: the two ZPI/FXa complex structures (one built from the
homology approach and the other from the docking approach), the crystal structure of AT3/
FXa complex (PDB code 2GD4)— modified to include missing N-terminal regions and to
mutate the active site Ala195 of FXa back to serine—and additionally a modified version of
the AT3/FXa complex structure, in which the P1 arginine in AT3 was mutated to an alanine.
All structures were solvated in a 12.5 Å layer of TIP3P water molecules [32] and neutralized
using Na+ or Cl− ions. Prior to structural equilibration, the systems were subjected to several
stages of energy minimization and relaxation. In the first step, belly dynamics was performed
on all the water molecules and counterions for 25 ps. This involved allowing motional freedom
to the water molecules and the counterions to relax their positions, while the protein atoms
were kept fixed. This was followed by an energy minimization of all the water molecules and
counterions in 20,000 conjugate gradient steps to remove steric clashes, while the protein was
held fixed. The whole system was then subjected to minimization in 1,000 steps of steepest
descent, followed by 50,000 conjugate gradient steps. A stepwise, constant volume heating
procedure was implemented over a 70 ps period to bring the system to 300 K, and then held at
300 K for another 100 ps, before starting constant pressure simulations for density
equilibration. Equilibration times varied for different systems, and were followed by an
unconstrained production run. Long-range electrostatic interactions were treated using the
particle mesh Ewald (PME) method [33,34], and a time step of 1.5 fs was used for all of the
MD calculations. The ZPI/FXa complex built through the docking method was subjected to a
self-guided MD simulation (SGMD) [35], to enhance conformational sampling efficiency.
Since our aim was to examine whether the conformation of ZPI/FXa obtained through docking
moved towards the conformation obtained through homology modeling or if it explored a
different conformational path, we used SGMD to accelerate the systematic motions by applying
a guiding force during the simulation. The motivation behind using accelerated conformational
sampling was to obtain a qualitative idea, in a reasonable timescale, regarding the direction of
movement of ZPI in the ZPI/FXa complex obtained through the docking method. A local
sampling time of 2.0 ps and a guiding temperature of 1.0 K, which defines the strength of the
guiding force in temperature units, were used for the SGMD method. The guiding force was
applied to a part of the simulation system that included only the ZPI atoms. The stability of
the system and the state of equilibration in each of the simulations were followed by monitoring
the backbone root mean square deviation (RMSD) and the potential energy of the system.
The MM-PBSA method [17] was applied to estimate the free energies of binding from the
molecular mechanical force field energy (EMM), and the solvation free energies (Gnonpolar +
GPB) for the ZPI/FXa and AT3/FXa complex structures. This method is based on analysis of
conformations obtained from MD simulations of the different systems and computing different
energetic terms between the complex and both the serpin and the protease. Simulations of the
serpin–protease complexes and the unbound proteins were used to extract the final 100
structural snapshots of the complexes and the unbound proteins after equilibration, which were
then stripped of water molecules and counterions and the total free energy of the system is
estimated as a sum of the following energy contributions,
where EMM is the forcefield energy computed from the snapshots in the MD simulation as the
contribution from electrostatic (Eele) and van der Waals (EVDW) energetic interactions for the
complex, Gnonpolar for the nonpolar contribution to the solvation free energy based on solvent
accessible surface area (SASA) calculation, and GPB stands for the electrostatic part of the
solvation free energy obtained by solving the Poisson-Boltzmann equation. Since an estimate
of solute entropy is not included, the subsequent free energies are not absolute, but instead
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relative. Free energies of binding for the serpin–protease complex can be then estimated
according to the following equation, where «X» corresponds to an average of a given value X
over a sequence of snapshots taken from MD trajectories:
This procedure has been used successfully to estimate absolute [36,37] and relative [38,39]
free energies of binding in protein–protein systems.
Results and discussion
Structural model of ZPI/FXa
The basic objective of our work was to build a 3D structural model of the ZPI/FXa complex,
making use of homology information from previously resolved protein crystal structures. In
one approach, the crystal structure of the AT3/FXa complex was used as the template, as ZPI
shares significant homology with AT3 and also inhibits FXa through a similar serpin inhibitory
mechanism [3]. The amino acid sequence alignment of human ZPI and AT3 showed 28%
sequence identity (~50% similarity), when the non-conserved N-terminal tail region (residue
1–52) was excluded. All serpins, despite relatively low pairwise identity of primary structures
(sometimes as low as 25%), share an extensive, common fold [2]. The sequence identities
between AT3 and other blood coagulation serpins with known structure, namely HCII and
A1AT are only 29% and 31%, respectively (excluding the N-terminal tail region), and yet they
share significant structural similarity in their protein core. The protein core here is defined as
the entire structure of the serpin excluding the peripheral elements of secondary structure,
namely the N-terminal tail preceding the helix A and the approximately six residue long C-
terminal tail region following sheet B. The RMSDs of the backbone atoms of AT3 with HCII
and A1AT in their core regions are 1.14 Å and 1.41 Å, respectively. So, while it is generally
held that greater than 30% identity between the target and template sequence is desirable for
comparative modeling, in the case of serpins, a sequence identity of 28% between ZPI and
AT3 offers a reasonable starting point for homology modeling.
The second model of the ZPI/FXa complex was built by first constructing a structural model
of ZPI alone, using a multiple sequence alignment with AT3, HCII and A1AT (28, 29 and 32%
sequence identity, respectively). The best solvent-equilibrated structural model of ZPI was then
docked to FXa using protein–protein docking. Although this second model of ZPI presented
a different interaction surface to FXa, and had a significantly different orientation of ZPI with
respect to the first model, it was observed that, after a long self-guided MD simulation (26 ns),
ZPI reoriented extensively with respect to FXa in this model and moved in the direction of the
ZPI orientation in the first model, built through the homology approach from AT3/FXa.
Therefore, the best model of the ZPI/FXa complex built through the first approach was used
for structural refinement and analyses. It must be emphasized that there were no constraints
imposed to effect this movement, and the SGMD movement in the second model could in
principle have been in any direction. PROCHECK was used to calculate the ϕ–ψ angles for
the Ramachandran plot, which shows that most of the ϕ–ψangles (83.0%) were located in the
core region of the plot, and only 1.0% were in the disallowed region for the starting ZPI/FXa
model (Fig. S1). For comparison, the same assessment was applied to the X-ray crystal structure
of AT3/FXa (2GD4); it was found that 84.7% of ϕ–ψangles were located in the core regions
and 0.3% were in the disallowed region. Thus, the fraction of residues in the modeled structure
deviating from expected ϕ–ψRamachandran regions is comparable to that for the X-ray crystal
structure of AT3/FXa. The improper geometries in the starting model were further refined
using MD simulation (discussed below). The model was also assessed using the Verify3D
algorithm (Fig. S2) that shows the 3D to one-dimensional (1D) scores of our model are similar
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to those obtained with the template structure of AT3. The values are mostly positive, except
for the few residues around the P1 region that directly interact with FXa, which indicate that
the structure has properly folded.
MD simulation of ZPI/FXa
The quality of the initial model was improved by subjecting it to several stages of energy
minimization and relaxation, followed by unconstrained MD production run in an aqueous
environment until stable conformations with near constant RMSD values were reached. The
steric clashes and improper geometries in the initial structure were removed after the MD
simulation, to obtain a model with correct bond lengths and bond angles, and where individual
atoms were clash-free. All of the residues in the disallowed regions of the ϕ–ψmap migrated
into the allowed regions. The RMSD values comparing a series of structural snapshots of ZPI/
FXa, taken at 3 ps intervals during the course of a 25 ns simulation, to the first ZPI/FXa snapshot
are shown in Fig. 2a. The figure shows the backbone RMSD versus time for different structural
regions of ZPI/FXa complex, calculated during the simulation. The plot shows that, after 15
ns of simulation time, the structures of ZPI and FXa have equilibrated and their backbone
RMSDs were around 4.5 Å and 1.5 Å, respectively, compared to the starting structure. The
high RMSD for ZPI is due to the flexible N-terminal tail region; when the N-terminal region
was not included, the RMSD is approximately 3 Å from the starting structure. The N-terminal
tail region is relatively unconstrained by packing, with few secondary structural features,
leading to its increased flexibility. The RMSD for the overall serpin–protease complex,
however, fluctuated between 4.5 and 7 Å due to the heightened mobility at the complex
interface; a similar phenomenon is observed in a 17 ns control simulation of the solvated AT3/
FXa X-ray crystal structure (Fig. 2b).
To identify the mobile structural elements, the atomic positional fluctuations for all the ZPI/
FXa backbone atoms were monitored during the simulation time. A residue-based description
of the local flexibility was obtained by calculating root mean square fluctuation (RMSF) values.
The RMSF values describe the atomic positional fluctuations of the structure after fitting it to
a reference frame, which in this case was the starting structure of the selected part of the
trajectory. The difference between RMSD and RMSF values is that in the latter, the average
is taken over time, giving a value for each residue (or atom) i, whereas with RMSD the average
is taken over the residues, giving time-specific values. The backbone RMSF values calculated
over the final 3 ns of the trajectories and averaged over each residue for the FXa (both AT3
and ZPI bound) and serpin (AT3 and ZPI) structures are shown in Fig. 3a, b.
There is a significant level of similarity in the RMSF values for FXa, bound to both AT3 and
ZPI (Fig. 3a). Plots of the RMSF data indicated that the largest atomic positional motions of
ZPI/FXa and AT3/FXa complexes occurred in the approximately 50 amino acid residue long
N-terminal tail region of the serpins (Fig. 3b). The fluctuation in ZPI for that region reaches a
value of around 6.5 Å; in the same region of AT3, the fluctuation is smaller, the corresponding
RMSF value being around 4.5 Å. Overall, the values of fluctuation in ZPI are slightly higher
than for the AT3 structure, but the overall plot is generally similar between the two structures.
The higher atomic fluctuation in ZPI is as expected, because of the absence of three disulfide
bonds in ZPI compared to AT3 (at positions 8–128, 21–95 and 247–430). Other regions in ZPI
that had higher RMSF values compared to their corresponding regions in AT3 include certain
loop regions connecting the secondary structural elements (residues 110–118 preceding helix
D, residues 149–154 located before helix E, residues 193–195 following helix F, residues 351–
355 below sheet A) and residues 376–382 located N-terminal to the reactive site in the flexible
RCL region. The regions in ZPI that are more flexible compared to AT3 are highlighted in Fig.
4.
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With the exception of protein C inhibitor, the heparin-binding serpins appear to use a
structurally homologous region (helix D) as part of the positively charged heparin binding site
[2,40]. It was observed in a previous study that heparin did not significantly affect the ZPI
inhibition of FXa in the presence of PZ, and increased the inhibitory activity to only a minor
extent in the absence of PZ [4]. Comparing the heparin-binding region of AT3 to the
corresponding region of ZPI shows that ZPI does not possess as many positively charged
residues near helix D as in AT3 and the key residues involved in the interaction of heparin
pentasaccharide with AT3 (PDB code 2GD4) are poorly conserved [41]. The surrounding
region in ZPI, which contains residues 26–43, is in fact highly negatively charged and shows
little homology to AT3 (Fig. 5). The acidic tail region shows some similarity to HCII, which
also contains several acidic amino acid residues [22]. It is therefore likely that the weak effect
of heparin on ZPI inhibition of FXa [4] is probably due to the inability of heparin to bind with
significant affinity to this region.
The role of the flexible N-terminal tail region in ZPI is yet to be defined. The absence of two
corresponding disulfide bonds in ZPI in this region compared to AT3 gives significant mobility
and, unlike AT3, the movement of this flexible region is not coupled with helix D. The same
two disulfide bonds are also absent in HCII, conferring significant mobility to the tail region
in HCII compared to AT3. In the native structure of HCII, the N-terminal tail is sequestered
through an interaction with the highly basic heparin binding region [42]. Binding of heparin
releases the tail region, thus making it available for interaction with an exosite region in
thrombin. In the crystal structure of the HCII-thrombin Michaelis complex, the acidic N-
terminal tail forms ionic and hydrophobic contacts with exosite regions on thrombin through
an allosteric mechanism [22]. In our 25 ns simulation of solvated ZPI/FXa, although there were
significant atomic fluctuations and mobility in the N-terminal tail region, the tail did not move
so as to interact directly with FXa. It is not clear whether this is due to inadequate sampling in
our simulation or because the tail region is involved in extended intramolecular interactions
with several positively charged residues in ZPI (Lys104, Arg105, Lys125, Arg133, and
Arg163) that restricts its movement. Deletion of the N-terminal region in HCII abolished most
of the glycosaminoglycans (GAG)-induced enhancement in inhibiting thrombin, indicating the
importance of this region [43,44]. Constructing and expressing a truncated form of ZPI without
the N-terminal tail (tail deleted variant of ZPI) would similarly help to understand the function
of this flexible region in inhibition of FXa and its potential role in binding to PZ.
MM-PBSA calculations
The ensembles of structural snapshots obtained from the MD simulations of ZPI/FXa and AT3/
FXa were used to perform MM-PBSA calculations in order to estimate binding free energies
of FXa to both ZPI and AT3. In addition, two separate MD simulations of AT3/FXa in which
the P1 arginine residue in AT3 was mutated to alanine or tyrosine were performed and included
in the calculations, to estimate the binding contribution from the P1 residue. These calculations
resulted in a ΔGbinding of −276.66±11.30 kcal mol−1 for FXa binding to wild-type AT3, and a
ΔGbinding of −262.48±11.59 kcal mol−1 for binding to wild-type ZPI. Since these calculations
do not include solute entropic corrections, they provide only relative free energies. The MM-
PBSA calculations in this study are used primarily to estimate a relative measure of the affinities
of binding for the different complex structures, and are not intended as estimates of true binding
energies. The calculations predict a stronger binding of AT3 to FXa than ZPI, with ΔGbinding
of −14.18 kcal mol−1. Table 1 shows all the energy contributions for the different complexes
along with the standard deviation values, as deduced from the MM-PBSA analysis. In order
to further explore the difference in the relative binding affinity between AT3 and ZPI to FXa,
similar calculations were performed on R393A and R393Y AT3/FXa complexes. These
calculations resulted in a ΔGbinding of −243.46± 10.17 kcal mol−1 for FXa binding to R393A
AT3, and a Δ3Gbinding of −264.60±10.22 kcal mol−1 for binding to R393Y AT3. The difference
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in the binding free energy between wild type AT3 and the P1 Ala substitution mutant
(Δ3Gbinding of −33.2 kcal mol−1) is consistent with the critical role played by the Arg393
residue in the interaction with FXa. When the P1 residue in AT3 was mutated to a tyrosine
(R393Y), the relative binding energy of the complex (3Gbinding of −264.60±10.22 kcal
mol −1) is very close to the values observed in the ZPI/FXa complex (ΔGbinding of −262.48
±11.59 kcal mol−1). These MM-PBSA results indicate that the presence of an arginine residue
at the P1 position in AT3 creates a significant stabilization of the complex through an ionic
interaction with the S1 residue (Asp189) of FXa, and produces a higher binding affinity than
if alanine is present at the same position, or the P1 tyrosine residue present in ZPI.
Specific side chain interactions
The ability to form a productive non-covalent Michaelis complex depends primarily on specific
interactions between the RCL of the serpin and the active site region of the protease. But other
exosite interactions with the body of the serpin have also been observed in many serpin–
protease pairs. The extent of interactions between ZPI and FXa can be divided into two broad
regions: the RCL region and the sheet C region of ZPI. The RCL region is responsible for the
initial recognition of ZPI by FXa. In the non-covalent complex, our model has the P1 tyrosine
(Tyr387) side chain positioned in the S1 specificity pocket of FXa, and the RCL is involved
in extensive contacts with FXa. The contacts in the RCL region extend from residues P10 to
P3′ (residues Ala378–Pro390); these form complementary interactions with subsites in and
around the active site of FXa. In the case of AT3, a slightly larger set of residues (P9–P8′) in
the RCL region are involved in interactions with FXa (based on solvent-equilibrated MD
structure of the complex). Comparison of interaction between the critical P1 residue in ZPI
and AT3 with residues in the active site of FXa, shows some differences. In ZPI, while the P1
Tyr387 is involved in several hydrophobic, main chain and side chain hydrogen-bonding
interactions with FXa residues, it does not form an ionic interaction with the S1 residue
(Asp189) as seen in AT3, where the P1 Arg393 forms a salt bridge with the S1 residue. In
addition to this salt bridge interaction, Arg393 in AT3 is also involved in an aromatic interaction
with Tyr228 in FXa; this interaction is absent in ZPI. As a consequence, the side chain–side
chain distance between the P1 and S1 residues is larger in ZPI/FXa compared to AT3/FXa
(Fig. 6). This is consistent with experimental results that show that ZPI does not form an SDS-
stable complex with FXa, suggesting that, unlike the AT3/FXa complex, the ZPI/FXa complex
has a larger dissociation constant, probably owing to weaker active site–RCL recognition
interactions [3,4]. The P1–S1 side chain distance, however, does not affect the distance between
the active site Ser195 of FXa and the reactive bond in ZPI, i.e., ZPI is capable of forming the
covalent acyl ester linkage that results in the cleavage of the peptide bond between Tyr387 and
Ser388. The distance between Ser195 γO and the backbone carbon atom of Tyr387 of ZPI is
around 3.5–4.0 Å, which is similar to the distance observed in AT3. The simulation of R393A
AT3, for which the P1 arginine residue was mutated to an alanine, shows similar structural
characteristics, wherein the Ala393 side-chain lacks the salt bridge interaction with the S1
Asp189 of FXa but still has the reactive bond of the serpin within 3.5 Å of the active site Ser195.
This observation indicates that while the P1–S1 specificity interaction is important for the
stability and the binding affinity of the complex as shown from the MM-PBSA calculations,
the extended interactions between the RCL of the serpin and the active site of FXa contribute
towards maintaining the non-covalent complex between the enzyme and the substrate (or
inhibitor). This facilitates the subsequent formation of the covalent complex and the serpin
cleavage. In other words, the effectiveness of the serpin inhibition, which depends on the
formation of the covalent complex would be the same for ZPI and AT3, whereas the specificity
of the interaction with FXa would be more favorable for AT3 due to the presence of an arginine
at the P1 position compared to a tyrosine in ZPI. Table 2 shows a comparison of the specific
FXa residues involved in interaction with the RCL region of ZPI and AT3, based on the solvent-
equilibrated structural models obtained from our simulations.
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In the canonical view (Fig. 4) of the non-covalent serpin complex, FXa is positioned atop the
sheet C region of ZPI. So, in addition to the RCL interactions, residues in the sheet C region
of ZPI, specifically residues Pro224, Phe229, Tyr249, Ala251, Gly252, Asn311, Glu313 and
Phe315, are involved in interactions with FXa in this model. This is similar to interactions
found in AT3, for which several residues in the sheet C region (Glu232, Asn233, Arg235,
Glu237, Tyr253, Glu255 and His319) are involved in interactions with complementary residues
in FXa. Similar exosite interactions are also observed in the HCII-thrombin complex, where
residues in the sheet C region are involved in thrombin interactions.
Comparison with available experimental data, and location of known polymorphisms in the
structural model
Comparison of our structural predictions with available experimental information regarding
FXa residues predicted to be important for ZPI inhibitory activity [45] shows that, while our
structural model agrees with some of the basic residues identified in FXa by the experiments
as directly interacting with ZPI (Arg143, Lys147 and Arg150), most of the other basic residues
identified in that study are present on a surface of FXa that is distant from the ZPI interaction
surface in our model (Fig. 7). Therefore the significance of these other basic residues in binding
to ZPI is unclear. One possibility is that, although these residues are not involved directly in
interaction with the main body of the serpin, the flexible N-terminal tail region could still
potentially interact with these basic residues. The N-terminal region in ZPI, which is composed
of several acidic residues, is similar to the corresponding region in HCII and is unlike AT3, as
it lacks the two disulfide bonds that are present in AT3 in this region. This confers additional
mobility to the tail region in ZPI and could potentially enable its interactions with the basic
FXa residues through an allosteric mechanism. These basic residues in FXa (Arg93, Lys96,
Arg165, Lys169, Lys236 and Arg240) have also been implicated in heparin binding and are
thought to be important for bridging FXa with AT3 [46]. If the N-terminal tail of ZPI is in fact
involved in interactions with these basic residues of FXa, it could also explain why heparin
has only minimal effect on ZPI inhibitory activity [4], since the tail region would overlap the
heparin binding site on FXa. Another possibility is that, since the residues identified as
important through the experimental study are based on the reaction rate constants for ZPI
inhibition following their mutation, they do not correspond directly to the binding affinity of
those mutants for ZPI. These basic residues in FXa could also possibly play a role in its
interaction with the cofactor PZ. Table 3 lists the specific residues in ZPI and AT3 involved
in interaction with the basic exosite residues of FXa, based on data obtained from the solvent-
equilibrated structural model of the complexes. Experimental studies that explore the effect of
mutations of these residues to their binding with PZ could shed light on the nature of binding
interactions between FXa, ZPI and its non-proteinase ligand, PZ [47]. Our model thus identifies
specific residues predicted to be directly involved in the recognition and binding for testing by
mutagenesis experiments.
Our structural model of ZPI/FXa also provides us the opportunity to compare with a list of
mutations/polymorphisms found in a cohort of patients with venous thromboembolic diseases
[48]. Of the mutations, two (R67X and W303X) are stop mutations and have been considered
in subsequent studies [7,49–51]. However, an analysis of the location of the remaining
mutations shows that K25R and S40G are surface-exposed and located on the unstructured N-
terminal tail, G75S is also surface-exposed and located in the loop region between helix A and
helix B, S122T is surface-exposed and F124L is pointed towards the interior with both located
in helix D, L137Q is surface-exposed on a loop between helix D and the first strand of sheet
A, T140S is surface-exposed and is located on the first strand of sheet A, G250S is located in
sheet C at the interface region between ZPI and FXa, and Q363R is located on the third strand
of sheet A and is pointed towards the interior. Of these, G250S and Q363R appear to be located
in structurally important regions in our model. A recent study has revealed a charge–change
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R67Q mutation (rather than a stop mutation) [52]; this is located surface-exposed on helix A
in our structural model.
Summary
Comparative model building and solvent-equilibrated MD simulation study of the ZPI/FXa
non-covalent complex points to the overall similarities and specific differences between AT3/
FXa and ZPI/FXa Michaelis complexes. The atomistic structural model of ZPI/FXa gives a
structural rationale as to how ZPI acts as a serpin and inhibits FXa by binding to its active site.
Specific differences in the RCL and the sheet C region determine the relative specificity and
stability of the ZPI/FXa non-covalent complex. The role of the flexible N-terminal region and
the precise binding interaction of ZPI with PZ remain unclear. The binding interactions
identified from our solvent-equilibrated structural model offer starting points for experimental
verification of our model and for better understanding the interaction of ZPI with FXa.
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Refer to Web version on PubMed Central for supplementary material.
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Multiple sequence alignment of protein Z-dependent protease inhibitor (ZPI) with human
antithrombin III (AT3), α1-antitrypsin (A1AT) and heparin cofactor II (HCII) using ClustalW.
The N-terminal regions of the serpins share low homology and are not included in the figure.
β-sheets (arrows) and α-helices (cylinders) are indicated above the alignment. Asterisks denote
identity, colons strong similarity, and periods weak similarity. The reactive center loop
(RCL) and the P1 residue at the reactive center are indicated
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Plot of backbone root mean square deviation (RMSD) of a ZPI/factor Xa (FXa) over 25 ns
molecular dynamics (MD) simulation using the best homology model as a reference, and b
AT3/FXa over 17 ns simulation using the X-ray crystal structure (2GD4) as a reference. The
crystal structure of AT3 was modified to include missing regions and to mutate the active site
Ala195 of FXa back to serine
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Root mean square fluctuation (RMSF) of the backbone atoms averaged over each residue for
a the FXa regions bound to ZPI and AT3, and b the serpins, ZPI and AT3
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Cartoon representation of the solvent-equilibrated structural model of ZPI/FXa complex.
Structural elements colored in blue (also denoted by asterisks) highlight the regions of ZPI that
are comparatively more flexible than in AT3, as indicated by RMSF values obtained from the
simulation. The key secondary structural elements are labeled; P1 and the S1 residues are
shown in stick representation
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a,b Heparin binding region. a Residues involved in binding to heparin in AT3. b Residues in
the corresponding region of ZPI
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Distance between P1 and S1 residues in a ZPI/FXa and b AT3/FXa. ZPI and AT3 are shown
in cartoon representation with the portion of RCL region directly interacting with FXa colored
orange. The P1 and P1′ residues are shown in stick representation. The catalytic triad residues
and the S1 residue in FXa are also shown in stick representation (cyan) and colored by atom
type. The right-hand panel shows a plot of the distances between P1 and S1 and P1 and Ser195
over the simulation time for c ZPI/FXa, d AT3/FXa, and e R393A AT3/FXa. The plots show
that the P1–Ser195 distance is comparable between all three complexes, irrespective of their
P1–S1 distance
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Mapping of FXa basic residues predicted to be important for ZPI inhibition [43]. FXa is shown
in cartoon representation, with ZPI residues in stick representation and colored red. The
residues in FXa (stick representation and colored blue) make direct contacts with ZPI residues
(red), while the FXa residues colored gray are on a surface distant from ZPI
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Table 2
Comparison of specific residues in FXa involved in interaction with the reactive center loop (RCL) region of ZPI and
AT3. The interaction data is based on complete solvent-equilibrated structural model of the complexes
Interaction between FXa and the RCL loop of the serpins
Fxa ZPI RCL Position AT3 FXa
Arg222 Ala378 P10
Arg222 Gly379 P9 Ser385 Arg222
Arg222 Ile380 P8 Thr386 Gly218
Arg222 Leu381 P7 Ala387 Glu217, Arg222
Glu217 Ser382 P6 Val388 -
Phe174 Glu383 P5 Val389 Glu217
Tyr99, Phe174, Trp215 Ile384 P4 Ile390 Tyr99, Phe174, Trp215
Trp215, Gly216 Thr385 P3 Ala391 Trp215, Gly216





Tyr387 P1 Arg393 Asp189, Ala190, Gly193,
Asp194, Ser195, Ser214,
Gly218, Tyr228
His57, Gly193, Ser195 Ser388 P″ Ser394 His57, Gly193, Ser195
Phe41, Gly193 Met389 P″ Leu395 Phe41, Gly193
Arg143 Pro390 P″ Asn396 Phe41
P″ Pro397 Phe41, Ala61A
P″ Asn398 Asn35
P″ Arg399 Asn35, Glu37
P″ Val400 Glu37
P″ Thr401 Glu37
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Table 3
Residues in ZPI and AT3 involved in interaction with the basic exosite residues of FXa. The interaction data is based
on complete solvent-equilibrated structural model of the complexes
Interaction between serpins and the basic exosite residues of FXa
ZPI FXa basic residues AT3
- Lys96 -
Glu313, Tyr249 Arg143 Glu255, Tyr253
Pro224, Ala251, Glu375 Lys147 Glu232
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